Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Mirum Pharmaceuticals, Inc. < Previous 1 2 3 4 5 Next > Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences August 28, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 July 31, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older July 25, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC July 08, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX June 28, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies June 17, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 June 16, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress June 06, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older May 31, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress May 29, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting May 18, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 08, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference May 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC May 07, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 May 01, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 10, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome April 02, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis March 13, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences March 05, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI February 29, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update February 28, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 February 21, 2024 From Mirum Pharmaceuticals, Inc. Via Business Wire Tickers MIRM < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.